Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 407-416

  Kielberger, Lukas ^a   Bouda, Mirko ^a   Jindra, Pavel ^a   Reischig, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytomegalovirus disease; Pharmacoeconomic analysis; Prevention strategies; Renal transplantation

Indexed keywords

GANCICLOVIR; VALACICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; ECONOMICS, PHARMACEUTICAL; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; VALINE;

EID: 84860796334     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000335962     Document Type: Article

References (32)

1. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
2. Sagedal S, Hartmann A, Nordal KP, et al: Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337.
3. Sagedal S, Rollag H, Hartmann A: Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21: 309-313.
4. Reischig T, Jindra P, Svecova M, Kormunda S, Opatrný K Jr, Treska V: The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36: 146-151.
5. Reischig T: Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 2010; 8: 903-910.
6. Sagedal S, Nordal KP, Hartmann A, et al: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
7. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland SER, Matas AJ: Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879-1883.
8. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V: Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87: 436-444.
9. Das A: Cytomegalovirus infection in solid organ transplantation: Economic implications. Pharmacoeconomics 2003; 21: 467-475.
10. McCarthy JM, Karim MA, Krueger H, Keown PA: The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277-1282.
11. Humar A, Snydman D, AST Infectious Diseases Community of Practice: Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4):S78-S86.
12. Kotton CN, Kumar D, Caliendo AM, et al: International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
13. Reischig T, Jindra P, Mares J, et al: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005; 79: 317-324.
14. Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69-77.
15. Lowance D, Neumayer H-H, Legendre CM, et al: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462-1470.
16. Paya C, Humar A, Dominguez E, et al: Efficacy and safety of valganciclovir v.s. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
17. Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al: A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect 2005; 11: 736-743.
18. Khoury JA, Storch GA, Bohl DL, et al: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
19. Tilden DP, Chapman J, Davey PJ, Solly ML, Crowley S: A decision-analytic economic evaluation of valacyclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clin Transplant 2004; 18: 312-320.
20. Legendre CM, Norman DJ, Keating MR: Valacyclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: An economic evaluation. Transplantation 2000; 70: 1463-1468.
21. Squifflet J, Legendre C: The economic value of valacyclovir prophylaxis in transplantation. J Infect Dis 2002; 186(suppl 1):116-122.
22. Hagenmeyer EG, Häussler B, Hempel E, et al: Resource use and treatment costs after kidney transplantation: Impact of demographic factors, comorbidities, and complications. Transplantation 2004; 77: 1545-1560.
23. Kim WR, Badley AD, Wiesner RH, et al: The economic impact of cytomegalovirus unfection after liver transplantation. Transplantation 2000; 69: 357-361.
24. Schnitzler, MA, Lowell, JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC: The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant 2003; 3: 445-451.
25. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A: Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449-2458.
26. Luan FL, Kommareddi M, Ojo AO: Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation 2011; 91: 237-244.
27. Brennan DC, Garlock KA, Singer GG, et al: Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846.
28. Legendre C, Beard SM, Crochard A, et al: The cost-effectiveness of prophylaxis with valacyclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ 2005; 6: 172-182.
29. Paya C, Humar A, Dominiguez E, et al: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
30. Humar A, Lebranchu Y, Vincenti F, et al: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
31. Blumberg EA, Hauser IA, Stanisic S, et al: Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation 2010; 90: 1420-1426.
32. Opelz G, Döhler B: Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85: 661-666.